Close
FINDING CURES TOGETHER<sup>SM</sup>

Media Advisories

 

 

Leading Cancer Research Organizations to Host International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Oct. 26-30219489/21/2017 4:56:30 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx93False2017-09-21T16:00:00Z<div class="ExternalClassAF09F8644CD54B40806BC195F535E158"><p>PHILADELPHIA — The American Association for Cancer Research (AACR), the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (EORTC) will host their annual <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=113#.WcGIpciGOUk">International Conference on Molecular Targets and Cancer Therapeutics </a>Oct. 26-30 at the Pennsylvania Convention Center in Philadelphia.</p><p>The Molecular Targets and Cancer Therapeutics conference is the premier international meeting featuring novel cancer therapeutics. It will bring together academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.</p><p>The full program is available <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=113&amp;DetailItemID=680">here</a>.</p><p>Registration is complimentary for credentialed news media and public information officers at medical institutes and cancer centers by contacting Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155.</p><p>Those following on social media can join the conversation on Twitter at <a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23Targets17">#Targets17</a>.</p><p>For more information, contact Julia Gunther at <a href="mailto&#58;julia.gunther@aacr.org">julia.gunther@aacr.org</a> or 215-446-6896, or Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155.</p></div>
Leading Cancer Research Organizations to Host Cancer Immunotherapy Conference215528/16/2017 9:02:15 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx92False2017-08-16T20:00:00Z<div class="ExternalClassDDB3A8AAD9404BAAAF416B7A2C619C68"><p>PHILADELPHIA – The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the third <a href="http&#58;//www.cancerimmunotherapyconference.org/" target="_blank">International Cancer Immunotherapy Conference </a>at the Rheingoldhalle Congress Center in Mainz/Frankfurt, Germany, Sept. 6-9, 2017.</p><p>The program will focus on &quot;Translating Science into Survival,&quot; and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy, including neoantigens and vaccines, novel mechanisms of immunosuppression and immune evasion, biomarkers, microbiota, oncolytic viruses, new agents and their modes of action, combination therapies, adoptive cell therapies, new checkpoints, non-checkpoint immunotherapies, and the tumor microenvironment. </p><p>The full program is available <a href="http&#58;//www.cancerimmunotherapyconference.org/program-of-events">here</a>.</p><p>Registration is complimentary for credentialed news media. Members of the media can register by contacting Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org" target="_blank">lauren.riley@aacr.org</a> or 215-446-7155.</p><p>Public information officers at medical institutes and cancer centers can also register by contacting Lauren Riley.</p><p>For more information, contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org" target="_blank">lauren.riley@aacr.org</a> or 215-446-7155, or Julia Gunther at <a href="mailto&#58;julia.gunther@aacr.org" target="_blank">julia.gunther@aacr.org</a> or 215-446-6896.<br></p></div>
AACR and FDA to Co-host Workshop on Immuno-Oncology212907/13/2017 7:18:56 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx91False2017-07-13T19:00:00Z<div class="ExternalClass54D5004CB6E64016AAC3DA5F64E5F59A"><p>The U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) present a workshop on immuno-oncology combination therapies.</p><p>This workshop is the third in a series, designed to bring together leading experts across the immuno-oncology drug development community to foster robust scientific discussion about the regulatory process to accommodate the fast pace of innovation in science and technology.</p><p>This year’s workshop will focus on approaches to combination therapy and best practices regarding patient and dose selection, biomarkers to aid in selection, and novel endpoints that can define patient benefit.&#160;&#160; </p><p><strong>WHEN&#58;</strong><br>Thursday, July 20<br>8 a.m. to 4 p.m.</p><p>In-person or live stream attendance is free but registration is requested.</p><p><strong>WHERE&#58;</strong><br>W Washington D.C. Hotel<br>515 15th Street, NW<br>Washington, D.C.</p><p><strong>SPEAKERS AND PROGRAM&#58;</strong><br>Interviews can be arranged per the availability of the speakers.</p><p><strong>Chair, U.S. Food and Drug Administration</strong><br>Amy E. McKee, MD, Supervisory Associate Director, Office of Hematology and Oncology, Center for Drug Evaluation and Research, FDA</p><p><strong>Chair, American Association for Cancer Research</strong><br>Elizabeth M. Jaffee, MD, AACR President-Elect; Deputy Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</p><p><strong>Part I&#58;&#160; Immuno-Oncology Overview—Scope of the Problem</strong><br>Robert H. Vonderheide, MD, DPhil, Abramson Cancer Center, University of Pennsylvania<br>David F. McDermott, MD, Beth Israel Deaconess Medical Center<br>Leisha A. Emens, MD, PhD, Johns Hopkins University School of Medicine<br>Joaquim Bellmunt, MD, PhD, Harvard Medical School; Dana-Farber Cancer Institute<br>Nolan A. Wages, PhD, University of Virginia&#160; <br>Daniel S. Chen, MD, PhD, Genentech Inc.</p><p><strong>Part II&#58;&#160; Key Translational and Design Questions for Immuno-Oncology Agents</strong><br>Tiffany K. Ricks, PhD, FDA<br>Bernard A. Fox, PhD, Earle A. Chiles Research Institute<br>David F. McDermott, MD, Beth Israel Deaconess Medical Center <br>Marc R. Theoret, MD, FDA </p><p><strong>Part III&#58;&#160; Considerations for Dose Selection of Immuno-Oncology Combination Products</strong><br>Chao Liu, PhD, and Laura L. Fernandes, PhD, FDA<br>Amit Roy, PhD, Bristol-Myers Squibb<br>Eric H. Rubin, MD, Merck<br>Israel Lowy, MD, PhD, Regeneron Pharmaceuticals, Inc.<br>René Bruno, PhD, Genentech, Inc./Roche<br>Nolan A. Wages, PhD, University of Virginia <br>Lei Nie, PhD, FDA&#160; <br>Qi Liu, PhD, FDA</p><p><a href="/AdvocacyPolicy/GovernmentAffairs/Documents/2017%20FDA-AACR%20Oncology%20Dose%20Finding%20Workshop%20Agenda.pdf">View </a>the full program.</p><p>​To attend or access the live stream, please RSVP to Rachel Salis-Silverman at <a href="mailto&#58;rachel.silverman@aacr.org" target="_blank">rachel.silverman@aacr.org</a> or 215-446-7159.</p></div>
AACR and SITC to Host a Congressional Briefing Highlighting Immunotherapy’s Progress and Its Benefit to Patients212847/12/2017 7:12:17 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx90False2017-07-12T19:00:00Z<div class="ExternalClassE23A9E58D1064EFEB42E9C7ACA528CBE"><p>​WHAT&#58;&#160; The American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC) will co-host a congressional briefing titled, “Progress in Immunotherapy&#58; Delivering Hope and Clinical Benefit to Cancer Patients,” to highlight some of the exciting innovations in the field of immunotherapy, illustrate the hope that these advances are bringing to patients, and note the challenges that still need to be overcome so that even more patients can benefit from these revolutionary treatments.</p><p>For many patients, cancer immunotherapies are providing lifesaving results where other treatments had failed or were not viable. But realizing more breakthroughs in this area and increasing the number of types of cancers that can be treated with immunotherapy requires a sustained, federal investment in cancer research through the National Institutes of Health and the National Cancer Institute.</p><p>WHEN&#58;&#160;Wednesday, July 19<br>Noon to 1&#58;30 p.m.</p><p>WHERE&#58;&#160;Russell Senate Office Building, Room 485<br>Capitol Hill<br>&#160;<br>WHO&#58;&#160; &#160;<strong>Elizabeth M. Jaffee, MD</strong>, AACR President-Elect 2017-2018; Chair, National Cancer Institute’s National Cancer Advisory Board; Member, Biden Cancer Initiative Board of Directors; Deputy Director,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore<br><strong>Lisa H. Butterfield, PhD</strong>, President, SITC; Professor of Medicine, Surgery and Immunology; and Director, UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh<br><strong>Steven A. Rosenberg, MD, PhD</strong>, Chief of Surgery, National Cancer Institute, Bethesda, Maryland<br><strong>Bernard A. Fox, PhD</strong>, Past President, SITC; Chief, Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.<br><strong>Daniel S. Chen, MD, PhD</strong>, Vice President, Global Head of Cancer <br>Immunotherapy Development, Genentech, South San Francisco <strong>Stefanie Joho</strong>, colon cancer survivor who benefited from immunotherapy</p><p>The AACR appreciates Senator Chris Van Hollen’s (D-Maryland) assistance with logistics for this congressional briefing.<br></p></div>
First Analyses of AACR Project GENIE Data to Be Featured in Major Symposium at Annual Meeting 2017201953/28/2017 4:18:03 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx89False2017-03-28T16:00:00Z<div class="ExternalClass0C2E3384412C49718B929C674191131B"><p>WASHINGTON — Analyses from the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) will be presented during a special session, <a href="http&#58;//media.ne.cision.com/l/gezakkxu/www.abstractsonline.com/pp8/#%21/4292/session/57">SY12 - Pan-Cancer Genomic Analysis</a>, April 3 at 10&#58;30 a.m. ET in Ballroom A-B in the Walter E. Washington Convention Center during the <a href="http&#58;//media.ne.cision.com/l/gezakkxu/www.aacr.org/MEETINGS/PAGES/MEETINGDETAIL.ASPX?EVENTITEMID=105">AACR Annual Meeting 2017</a>.</p><p><a href="http&#58;//media.ne.cision.com/l/gezakkxu/www.aacr.org/RESEARCH/RESEARCH/PAGES/AACR-PROJECT-GENIE.ASPX">AACR Project GENIE </a>is a multi-phase, multi-year, international data-sharing project that catalyzes precision oncology through the development of a regulatory-grade registry that aggregates and links clinical-grade cancer genomic data with clinical outcomes from tens of thousands of cancer patients treated at multiple international institutions.</p><p>For additional information on AACR Project GENIE, please read this interview with AACR Past President and Project GENIE Steering Committee Chairperson Charles Sawyers, MD, FAACR, on the AACR’s blog, Cancer Research Catalyst, <a href="http&#58;//media.ne.cision.com/l/gezakkxu/blog.aacr.org/aacr-project-genie-advancing-cancer-research-through-data-sharing">here</a>.</p><p>Follow the AACR Annual Meeting 2017 on Twitter&#58; <a href="https&#58;//wpyadmin.ne.cision.com/l/gezakkxu/twitter.com/hashtag/AACR17?src=hash">#AACR17 </a></p></div>
American Association for Cancer Research to Hold Its Annual Meeting in Washington, April 1-5, 2017113743/15/2017 4:13:15 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx88False2017-03-15T15:00:00Z<div class="ExternalClass531946E5678C484E995913307C2FD322"><p>​PHILADELPHIA – The American Association for Cancer Research (AACR) will be hosting its <a href="http&#58;//media.ne.cision.com/l/yihljruu/www.aacr.org/MEETINGS/PAGES/MEETINGDETAIL.ASPX?EVENTITEMID=105" target="_blank">Annual Meeting</a>, April 1-5, at the Walter E. Washington Convention Center in Washington, D.C.</p><p>The meeting is expected to draw more than 20,000 scientists, clinicians, advocates, and others to discuss advances in the field of cancer science. The multidisciplinary program will include an outstanding roster of speakers, hundreds of invited talks, and more than 6,000 proffered papers.</p><p>View the meeting program <a href="http&#58;//media.ne.cision.com/l/yihljruu/www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105&amp;DetailItemID=540" target="_blank">here</a>.</p><p>Press conferences will take place in Room 154 of the convention center (801 Mount Vernon Place NW, Washington, D.C. 20001) during the following days/times&#58;</p><p>•&#160;Sunday, April 2<br>11 a.m. ET<br>•&#160;Monday and Tuesday, April 3 and 4<br>8&#58;30 a.m. ET</p><p>The press office will be located in Room 149 of the convention center and will be open during the following days/times&#58;</p><p>•&#160;Saturday, April 1&#58;<br>8 a.m. to 6 p.m. ET<br>•&#160;Sunday, Monday, and Tuesday, April 2, 3, and 4&#58;<br>7&#58;30 a.m. to 6 p.m. ET<br>•&#160;Wednesday, April 5&#58;<br>7&#58;30 a.m. to noon ET</p><p>An embargoed press kit containing news releases and highlighted abstracts will be available to news media the week prior to the start of the conference.</p><p>Registration is complimentary for credentialed news media. Members of the media can register by contacting Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155.</p><p>Reporters planning to cover remotely should also register so that they receive all relevant communications sent out by the AACR Department of Communications and Public Relations during the meeting.</p><p>Public information officers at medical institutes and cancer centers (limit two PIOs per institution) can also register by contacting Riley.</p><p>On Saturday, April 1 from 8&#58;30 a.m. to 12&#58;15 p.m., the AACR will host its signature community event, Progress and Promise Against Cancer, offering practical knowledge and real hope to cancer patients, survivors and anyone interested in cancer science. Hosted by AACR President-Elect Michael Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and chief executive officer of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, this free event will feature preeminent national and D.C.-region experts discussing the latest advances in treatment, prevention, and how future health policies could impact patients. Patient advocates will share their inspiring stories, and attendees can connect with community resources in the Cancer Resource Partner Pavilion.&#160; View the experts and register here&#58; <a href="/cancerevent" target="_blank">www.aacr.org/cancerevent</a>.</p><p>Those following on social media can join the conversation on Twitter at <a href="https&#58;//wpyadmin.ne.cision.com/l/yihljruu/twitter.com/hashtag/AACR17?src=hash" target="_blank">#AACR17</a>.</p><p>For more information, contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155, Julia Gunther at <a href="mailto&#58;julia.gunther@aacr.org">julia.gunther@aacr.org</a> or 215-446-6896, or Jeff Molter at <a href="mailto&#58;jeff.molter@aacr.org">jeff.molter@aacr.org</a> or 267-210-3965.</p></div>
American Association for Cancer Research to Hold Its Annual Meeting in Washington, April 1-5, 2017191322/7/2017 2:11:07 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx87False2017-02-07T14:00:00Z<div class="ExternalClass6ACB3B48C8394026A3AB13833D01AAE0"><p>​PHILADELPHIA – The American Association for Cancer Research (AACR) will be hosting its <a href="/MEETINGS/PAGES/MEETINGDETAIL.ASPX?EVENTITEMID=105">Annual Meeting</a>, April 1-5, at the Walter E. Washington Convention Center in Washington, D.C.</p><p>The meeting will draw approximately 19,500 scientists, clinicians, advocates, and others to discuss advances in the field of cancer science. The multidisciplinary program will include an outstanding roster of speakers, hundreds of invited talks, and more than 6,000 proffered papers. </p><p>View the meeting program <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=105&amp;DetailItemID=540">here</a>. </p><p>Registration is complimentary for credentialed news media. Members of the media can register by contacting Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155.</p><p>Reporters planning to cover remotely should also register so that they receive all relevant communications sent out by the AACR Department of Communications and Public Relations during the meeting.</p><p>Public information officers at medical institutes and cancer centers (limit two PIOs per institution) can also register by contacting Riley.</p><p>The press room will be located in Room 149 of the Walter E. Washington Convention Center (801 Mount Vernon Place NW, Washington, D.C. 20001). The press room is a fully functioning office with computers, printers, wireless internet access, and refreshments for registered reporters. </p><p>Those following on social media can join the conversation on Twitter at <a href="https&#58;//twitter.com/hashtag/AACR17?src=hash">#AACR17</a>.</p><p>For more information, contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155, Julia Gunther at <a href="mailto&#58;julia.gunther@aacr.org">julia.gunther@aacr.org</a> or 215-446-6896, or Jeff Molter at <a href="mailto&#58;jeff.molter@aacr.org">jeff.molter@aacr.org</a> or 267-210-3965.<br></p></div>
Cancer Research Catalyst Blog: AACR Project GENIE Publicly Releases First Set of Genomic Data190271/5/2017 3:56:55 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx86False2017-01-05T15:30:00Z<div class="ExternalClass9DC342F60E1F4BF5B59D2201D4AE8211"><p>​The latest post on <a href="http&#58;//blog.aacr.org/"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), <a href="http&#58;//blog.aacr.org/aacr-project-genie-advancing-cancer-research-through-data-sharing/">features an interview</a> with AACR Past President Charles L. Sawyers, MD, FAACR, chairperson of the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE).</p><p>Sawyers discusses the new data release and the long-term goals of the project, which is a multi-phase, international data-sharing collaboration that began with eight hospitals and cancer centers in the United States, Canada, and Europe.</p><p>For more information on AACR Project GENIE, click <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=994">here</a>.</p><p>Visit the blog at <a href="http&#58;//blog.aacr.org/" target="_blank">http&#58;//blog.aacr.org</a> and subscribe. </p><p>Editor’s Note&#58; Media are welcome to freely repost and use excerpts, the infographics, or the video pieces. Please cite the source and link to blog.aacr.org&#58; “Originally posted on <em>Cancer Research Catalyst</em>, the official blog of the American Association for Cancer Research.”</p></div>
Cancer Today Winter Issue Addresses Screening Guidelines189891/4/2017 2:11:10 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx85False2017-01-04T13:30:00Z<div class="ExternalClass1D1CE65832D1429C9C9A20F9152E20F9"><p>​PHILADELPHIA — The Winter 2016/2017 issue of <a href="http&#58;//www.cancertodaymag.org/" target="_blank">Cancer Today</a>, a publication of the <a href="/Pages/Home.aspx">American Association for Cancer Research </a>(AACR), features “<a href="http&#58;//www.cancertodaymag.org/Winter2016/Pages/Screening-Gets-Personal-breast-cancer-prostate-cancer.aspx" target="_blank">Screening Gets Personal</a>.”&#160; Cancer screening guidelines have been a source of controversy. Tailored screening recommendations for groups and individuals may offer a way to increase benefits and reduce harms.</p><p>Published quarterly by the AACR, <em>Cancer Today </em>is an authoritative resource for cancer patients, survivors, and their family members and friends. In every issue, Cancer Today offers information and inspiration to help readers face the challenges of diagnosis, treatment, survivorship, and caregiving. </p><p>This issue of <em>Cancer Today </em>also includes “<a href="http&#58;//www.cancertodaymag.org/Winter2016/Pages/Going-Full-Bore-Susan-Leighton-Ovarian-Cancer-Survivor.aspx" target="_blank">Going Full Bore</a>,” a profile of Susan Leighton, an ovarian cancer survivor and passionate research advocate. “<a href="http&#58;//www.cancertodaymag.org/Winter2016/Pages/Making-a-Match-Combination-Immunotherapy-Risks-Benefits.aspx" target="_blank">Making a Match</a>” describes how combinations of drugs can be more effective than one drug working along, although combining treatments can increase the risk of side effects. “<a href="http&#58;//www.cancertodaymag.org/Winter2016/Pages/Faith-and-Fortitude-Cancer-Care-Poland-Cynthia-Ryan.aspx">Faith and Fortitude</a>” describes how a cancer center in rural Poland attempts to meet the medical and spiritual needs of its patients.</p><p>To read these stories and others, go to <a href="http&#58;//www.cancertodaymag.org/" target="_blank">Cancer Today</a>, or follow the magazine on Facebook at <a href="https&#58;//www.facebook.com/CancerToday" target="_blank">facebook.com/CancerToday </a>and Twitter at <a href="https&#58;//twitter.com/CancerTodayMag" target="_blank">twitter.com/CancerTodayMag</a>. </p><p>Media are welcome to use information from <em>Cancer Today</em>; however, we ask that you cite the source.</p></div>
MEDIA ALERT & PRESS TELECONFERENCE: 28th EORTC-NCI-AACR SYMPOSIUM1256011/21/2016 6:06:59 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx84False2016-11-21T18:00:00Z“Molecular Targets and Cancer Therapeutics”<div class="ExternalClassAFD4DC50453F4FB2B2A2D4D6FDB34F20"><p>MEDIA ALERT &amp; PRESS TELECONFERENCE</p><p>28th EORTC-NCI-AACR SYMPOSIUM<br>“Molecular Targets and Cancer Therapeutics”</p><p>Tuesday 29 November to Friday 2 December 2016, Munich, Germany.</p><p>A press conference will take place at 17.00 hrs CET (16.00 hrs GMT, 11.00 hrs ET) on Tuesday 29 November, Room Königssee, 2nd floor, ICM Messe München, Munich, Germany. This will include&#58;<br>•&#160;A joint statement by Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer (EORTC), and Margaret Foti, PhD, MD (hc), Chief Executive Officer of the American Association for Cancer Research (AACR), on the need for improved partnerships and funding for cancer research (embargoed to 18.00 hrs CET on Tuesday 29 November).<br>•&#160;A preview by Professor Jean-Charles Soria (chair of the Symposium executive scientific committee, EORTC) of groundbreaking research being presented on Thursday 1 December, focusing on three studies on targeted therapies and liquid biopsy (embargoed to 00.01 hrs CET on Thursday 1 December).<br>•&#160;Suggestions and navigational tips from Professor Soria, Professor Lee Helman (scientific co-chair, NCI) and Dr. George Demetri (member of the AACR Board of Directors) on sessions and presentations during the Symposium that the scientific committee think may be of interest to journalists.</p><p>If you want to join the press conference by telephone please email Gwydion Lyn&#58; <a href="mailto&#58;Gwydion.Lyn@ecco-org.eu">Gwydion.Lyn@ecco-org.eu</a> (copying in Emma Mason/Kerry Noble&#58; <a href="mailto&#58;info@ricemason.eu">info@ricemason.eu</a>) to register your interest and receive dial-in details.</p><p>There will be a full media programme and there is still time for journalists to register online&#58; <a href="http&#58;//www.ecco-org.eu/Events/ENA2016/Media" target="_blank">http&#58;//www.ecco-org.eu/Events/ENA2016/Media</a></p><p>NB&#58; you will need to register to join the press conference even if you are unable to attend the Symposium in Munich. </p><p>The media programme will include&#58;<br>•&#160;The revolution in our understanding of the molecular basis is leading to dramatic responses to targeted therapies in advanced and metastatic cancer&#58; results from three groundbreaking studies show early benefit to patients.<br>•&#160;What effect does alternately flooding and starving prostate cancer cells with testosterone have?<br>•&#160;Results from a trial of the experimental drug TAS-114 in combination with a 5-FU-based chemotherapy in patients with advanced non-small cell lung cancer, pancreatic, breast and colorectal cancers.<br>•&#160;Difficult-to-treat advanced soft tissue sarcomas respond to a combination of new and existing anti-cancer drugs.<br>•&#160;Results from a trial of LY3039478, a Notch inhibitor, in patients with advanced cancer of the breast, colon, paratid (salivary gland) and sarcoma.<br>•&#160;Latest results from a trial of a new drug, CB-839, in combination with everolimus in kidney cancer patients.</p><p>The EORTC, AACR and the USA’s National Cancer Institute (NCI) are joining forces for the Symposium&#58; <a href="http&#58;//www.ecco-org.eu/Events/ENA2016" target="_blank">http&#58;//www.ecco-org.eu/Events/ENA2016</a> where the latest advances in pre-clinical and clinical research will be presented. Around 2,200 international experts will be discussing innovations in drug development, target selection and the impact of new discoveries in molecular biology.</p><p>For media queries about the Symposium, contact&#58;</p><p>EORTC media consultants&#58;<br>Emma Mason<br>Email&#58; <a href="mailto&#58;wordmason@mac.com">wordmason@mac.com</a> <br>Mobile&#58; +44 (0)7711 296 986</p><p>Kerry Noble<br>Email&#58; <a href="mailto&#58;kerry_noble@hotmail.com">kerry_noble@hotmail.com</a> <br>Mobile&#58; +44 (0)7446 869 433</p><p>&#160;</p></div>